Imagine a world where two devastating conditions collide, creating a complex health challenge that affects thousands. This is the reality for individuals battling both cystic fibrosis and diabetes, a lesser-known complication called cystic fibrosis-related diabetes (CFRD). But here's where it gets even more critical: a groundbreaking partnership is stepping up to tackle this issue head-on. Diabetes Australia and Cystic Fibrosis Research Limited have joined forces in a strategic alliance, committing nearly $600,000 to advance research and innovations for CFRD. And this is the part most people miss—it’s not just about funding; it’s about putting the lived experiences of those affected at the heart of the research.
The partnership kicks off with an $80,000 investment to identify the most pressing priorities for the CFRD community. Why does this matter? Because CFRD is a unique and often misunderstood form of diabetes, stemming from progressive damage to the pancreas in cystic fibrosis patients. This damage leads to both insulin resistance and insufficiency, requiring specialized care that differs significantly from Type 1 or Type 2 diabetes. For the one in three people with cystic fibrosis who develop CFRD, managing this condition is crucial to protecting lung health, maintaining nutrition, and reducing infection risks.
But here’s where it gets controversial: While CFRD is one of the most common and serious complications of cystic fibrosis, it remains widely under-recognized and poorly understood. Is the medical community doing enough to address this gap? Diabetes Australia Group CEO Justine Cain believes this partnership is a bold step forward. “This collaboration will turn evidence into action, creating tangible improvements in people’s lives,” she said. “Cystic fibrosis is a devastating condition, but advancements in treatment have transformed outcomes. By focusing on genetic factors shared by both diabetes and cystic fibrosis, we can develop more effective management strategies.”
Cystic Fibrosis Research Limited Director Petrina Fraccaro echoed this sentiment, emphasizing the need to address misconceptions while centering research on real-world challenges. “As people with cystic fibrosis live longer, complications like CFRD demand urgent attention,” she explained. “This investment is a commitment to enhancing both quality of life and long-term health outcomes for our community.”
The first phase of funding will take a national approach, aiming to comprehensively understand the challenges faced by the CFRD community. This will pave the way for future research investments focused on evidence-based solutions. By March 2026, calls for project proposals are expected to open, inviting collaboration from aligned research funding agencies.
But here’s the question we’re left with: Can this partnership truly bridge the gap between medical research and the lived experiences of those affected? And what does this mean for the future of CFRD care? This initiative is part of Diabetes Australia’s 2025-2030 Research Strategy, which prioritizes research informed by real-life experiences. As we watch this partnership unfold, one thing is clear: the fight against CFRD is gaining momentum, and every voice—especially those of patients—matters.
What’s your take? Do you think this partnership will make a difference? Share your thoughts in the comments below—let’s spark a conversation that could shape the future of CFRD research.
For more information, visit Diabetes Australia’s current research projects.
About Cystic Fibrosis Research Limited (CFRL):
Established in 1990 by Cystic Fibrosis Queensland, CFRL is dedicated to growing bequests and donations to advance cystic fibrosis research. Their mission is to act as the custodian of a ‘Capital Fund’ to facilitate research, investigation, and ultimately, a cure for cystic fibrosis.
